aflitzy

Spectrum Pharma: CMS Rules in Favor of Zevalin

Positive news that should give a bump next week


.Semi-Annual Changes to the NASDAQ Biotechnology Index
8:02 pm ET 11/13/2009- GlobeNewswire
NEW YORK, Nov. 13, 2009 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced today the results of the semi-annual re-ranking of the NASDAQ BIOTECHnology Index(R) (Nasdaq:NBI), which will become effective with the market open on Monday, November 23, 2009.


The re-ranking will result in the following eight securities being added to the Index:


China Sky One Medical, Inc. (Nasdaq:CSKI), Hi-Tech Pharmacal Co., Inc. (Nasdaq:HITK), Poniard Pharmaceuticals, Inc. (Nasdaq:PARD), SIGA Technologies, Inc. (Nasdaq:SIGA), Spectrum Pharmaceuticals, Inc. (Nasdaq:SPPI), Targacept, Inc. (Nasdaq:TRGT), Vical Incorporated (Nasdaq:VICL), and Vanda Pharmaceuticals Inc. (Nasdaq:VNDA).


All securities are classified according to the Industry Classification Benchmark (ICB) as either biotechnology or pharmaceutical. The securities that meet the classification criteria then must meet other Index eligibility criteria including listing on the NASDAQ Global Market or the NASDAQ Global Select Market and meeting minimum requirements for market value, average daily share volume and seasoning as a public company. The Index is ranked on a semi-annual basis in May and November. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit indexes.nasdaqomx.com/.


As a result of the re-ranking, Matrixx Initiatives, Inc (Nasdaq:MTXX) will be removed from the Index.


The NASDAQ Biotechnology Index is the basis for the iShares Nasdaq Biotechnology Index(SM) Fund (IBB), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index. In addition, options based on the NASDAQ Biotechnology Index and the iShares Nasdaq Biotechnology Index Fund trade on various exchanges.

Five Drug Makers with Pending Catalysts

Hi Justin, would appreciate an update on the above mentioned stocks. Thanks in advance.

Five Drug Makers with Pending Catalysts

Looks like ENDP will need to wait until Dec as the FDA extended the review period.